AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference
Globe Newswire (Thu, 28-Mar 8:05 AM ET)
Globe Newswire (Tue, 26-Mar 9:05 AM ET)
Globe Newswire (Mon, 25-Mar 9:05 AM ET)
AIM ImmunoTech And 3 Other Stocks Under $3 Insiders Are Buying
Benzinga (Mon, 25-Mar 6:33 AM ET)
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
Globe Newswire (Fri, 22-Mar 8:55 AM ET)
AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM Opportunity
Globe Newswire (Fri, 15-Mar 8:45 AM ET)
AIM ImmunoTech Announces Launch of CEO Corner Platform
Globe Newswire (Thu, 7-Mar 8:45 AM ET)
Globe Newswire (Thu, 29-Feb 8:45 AM ET)
Globe Newswire (Wed, 14-Feb 8:55 AM ET)
Globe Newswire (Thu, 8-Feb 8:50 AM ET)
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders, viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases and drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple negative metastatic breast cancer. The company is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.
Aim Immunotech trades on the AMEX stock market under the symbol AIM.
As of March 28, 2024, AIM stock price climbed to $0.47 with 417,322 million shares trading.
AIM has a beta of 1.38, meaning it tends to be more sensitive to market movements. AIM has a correlation of 0.04 to the broad based SPY ETF.
AIM has a market cap of $23.00 million. This is considered a Sub-Micro Cap stock.
Last quarter Aim Immunotech reported $46,000 in Revenue and -$.16 earnings per share. This beat revenue expectation by $26,000 and missed earnings estimates by -$.05.
In the last 3 years, AIM stock traded as high as $2.51 and as low as $.29.
The top ETF exchange traded funds that AIM belongs to (by Net Assets): VTI, VXF.
AIM has underperformed the market in the last year with a return of +17.7%, while the SPY ETF gained +33.6%. In the last 3 month period, AIM fell short of the market, returning -4.5%, while SPY returned +10.1%. However, in the most recent 2 weeks AIM has outperformed the stock market by returning +30.8%, while SPY returned +1.7%.
AIM support price is $.41 and resistance is $.48 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AIM stock will trade within this expected range on the day.